Together with omega−3 fatty acids and other omega−6 fatty acids, arachidonic acid provides energy for body functions, contributes to cell membrane structure, and participates in the synthesis of eicosanoids, which have numerous roles in physiology as signaling molecules.
It was named after the similarly structured arachidic acid, a constituent of peanut oil whose name in turn derives from the ancient Greekneologismarachis 'peanut'. Peanut oil does not contain any arachidonic acid, itself. Arachidonate is the name of the derived carboxylate anion (conjugate base of the acid), salts, and some esters.
Some chemistry sources define 'arachidonic acid' to designate any of the eicosatetraenoic acids. However, almost all writings in biology, medicine, and nutrition limit the term to all cis-5,8,11,14-eicosatetraenoic acid.
In addition to being involved in cellular signaling as a lipid second messenger involved in the regulation of signaling enzymes, such as PLC-γ, PLC-δ, and PKC-α, -β, and -γ isoforms, arachidonic acid is a key inflammatory intermediate and can also act as a vasodilator. (Note separate synthetic pathways, as described in section below.)
Arachidonic acid is freed from phospholipids that contain an arachidonic acid sidechain by hydrolysis, catalyzed by the phospholipase A2 (PLA2).
Arachidonic acid for signaling purposes appears to be derived by the action of group IVA cytosolic phospholipase A2 (cPLA2, 85 kDa), whereas inflammatory arachidonic acid is generated by the action of a low-molecular-weight secretory PLA2 (sPLA2, 14-18 kDa).
Arachidonic acid is a precursor to a wide range of eicosanoids:
The enzymes 15-lipoxygenase-1 (ALOX15) and 15-lipoxygenase-2 (ALOX15B). ALOX15B catalyzes the oxidation of arachidonic acid to 15-hydroperoxyeicosatetraenoic acid (15-HPETE), which may then be further converted to 15-hydroxyeicosatetraenoic acid (15-HETE) and lipoxins; 15-Lipoxygenase-1 may also further metabolize 15-HPETE to eoxins in a pathway analogous to (and presumably using the same enzymes as used in) the pathway which metabolizes 5-HPETE to leukotrienes.
The enzyme 12-lipoxygenase (ALOX12) catalyzes oxidation of arachidonic acid to 12-hydroperoxyeicosatetraenoic acid (12-HPETE), which may then be metabolized to 12-hydroxyeicosatetraenoic acid (12-HETE) and to hepoxilins.
Arachidonic acid is also a precursor to anandamide.
The production of these derivatives and their actions in the body are collectively known as the "arachidonic acid cascade"; see Essential fatty acid interactions and the enzyme and metabolite linkages given in the previous paragraph for more details.
PLC may also be activated by MAP kinase. Activators of this pathway include PDGF and FGF.
In the body
Cell membranes
Along with other omega−6 and omega−3 fatty acids, arachidonic acid contributes to the structure of cell membranes. When incorporated into phospholipids, the omega fatty acid affects cell membrane properties, such as permeability and the activity of enzymes and cell-signaling mechanisms.
Brain
Arachidonic acid, one of the most abundant fatty acids in the brain, is present in similar quantities to docosahexaenoic acid, with the two accounting for about 20% of brain fatty-acid content. Arachidonic acid is involved in the early neurological development of infants.
Dietary supplement
This section is missing information about Typical dietary intake — needed to put supplement dose into context. Please expand the section to include this information. Further details may exist on the talk page.(February 2025)
Arachidonic acid is marketed as a dietary supplement. A 2019 review of clinical studies investigating the potential health effects of arachidonic acid supplementation of up to 1500mg per day on human health found there were no clear benefits. There were no adverse effects in adults of using high daily doses (1500mg) of arachidonic acid on several biomarkers of blood chemistry, immune function, and inflammation.
A 2009 review indicated that consumption of 5−10% of food energy from omega−6 fatty acids including arachidonic acid may reduce the risk of cardiovascular diseases compared to lower intakes. A 2014 meta-analysis of possible associations between heart disease risk and individual fatty acids reported a significantly reduced risk of heart disease with higher levels of EPA, DHA, and arachidonic acid.
Veterinary medicine
Cats have low Δ6 desaturase activity and cannot efficiently convert linoleic acid into arachidonic acid. As a result, they need to acquire it from food.
See also
Aspirin—inhibits cyclooxygenase enzyme, preventing conversion of arachidonic acid to other signal molecules